Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M

Lucid Diagnostics Inc.

2024-Q2 EPS reported -$0.62 revenue$1,977,000

EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
GAAP net loss $11.0M ($0.23/share); non-GAAP adjusted loss $9.7M ($0.20/share).
Positive clinical data: ENVET-BE study shows 2.4x increased yield; BE-1 study 88% sensitivity, 99% NPV.
Cash $24.9M after $11.6M Series B-1 preferred stock issuance; held CMS MAC Palmetto GBA MolDX meeting.
First major #CheckYourFoodTube event with upfront contracted payment; revenue cycle management improving.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.